ArticleMovement disorders : official journal of the Movement Disorder Society2026
Longitudinal Iron Changes in the Substantia Nigra of Early-Stage Parkinson's Disease.
Article in Movement disorders : official journal of the Movement Disorder Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HFE genotype influences substantia nigra iron accumulation and Parkinson's disease progression.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
backgroundProgression of substantia nigra pars compacta (SNc) iron content in early-stage Parkinson's patients (PD) is poorly understood.
objectiveTo determine if nigral iron measured by quantitative susceptibility mapping (QSM) with zero-referencing can track disease progression in early-stage PD.
methodsThirty-four early-stage PD patients and 35 matched controls were recruited. Iron content in the SNc and related regions were obtained using QSM with zero-referencing at both baseline and 1-year follow-up, along with clinical metrics.
resultsOf seven clinic metrics and five regional iron measures, only Movement Disorder Society-Unified Parkinson's Disease Rating Scale-Part II (MDS-UPDRS-II) (P = 0.046) and SNc iron (P = 0.0025 for cerebrospinal fluid zero-referencing; P = 0.014 for whole-brain zero-referencing) showed significant changes in PD subjects in the 1-year epoch. The changes in SNc iron were also correlated with changes in MDS-UPDRS-II (P = 0.004).
conclusionNigral iron content measured by zero-referencing QSM can be used to track disease progression in early-stage PD over the 1-year epoch. © 2026 International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
42698345What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.